TNF and juvenile idiopathic arthritis: Biologic therapies, most often anti-TNF and CTLA4 agents, were used as third and fourth line treatments following the JIA guideline recommendation to initiate biologic therapies for more severe, DMARD-resistant and/or polyarticular disease [11].